{"id":464,"date":"2023-11-02T22:22:56","date_gmt":"2023-11-02T22:22:56","guid":{"rendered":"https:\/\/actaecstg.wpenginepowered.com\/success\/estimation-du-risque-a-la-suite-dun-infarctus-evaluation-non-invasive-efficacite-du-dai-refine-icd\/"},"modified":"2023-11-10T22:20:58","modified_gmt":"2023-11-10T22:20:58","slug":"estimation-du-risque-a-la-suite-dun-infarctus-evaluation-non-invasive-efficacite-du-dai-refine-icd","status":"publish","type":"success","link":"https:\/\/act-aec.ca\/fr\/success\/estimation-du-risque-a-la-suite-dun-infarctus-evaluation-non-invasive-efficacite-du-dai-refine-icd\/","title":{"rendered":"Estimation du risque \u00e0 la suite d&rsquo;un infarctus \u00c9valuation non invasive &#8211; Efficacit\u00e9 du DAI (REFINE-ICD)"},"content":{"rendered":"\n<p><strong>Synopsis de l&rsquo;essai <\/strong>REFINE ICD teste si un d\u00e9fibrillateur cardioverteur implantable (DCI), en plus des soins habituels, modifiera la mortalit\u00e9 par rapport aux soins habituels seuls. Au total, 700 patients pr\u00e9sentant une FEVG comprise entre 36 % et 50 %, une HRT alt\u00e9r\u00e9e et une TWA anormale, mesur\u00e9e au moins 2 mois apr\u00e8s l&rsquo;infarctus, sont randomis\u00e9s. Les patients pr\u00e9sentant une DFM normale +\/- une MPT ne sont pas \u00e9ligibles pour la randomisation mais sont suivis dans un registre.  <\/p>\n\n<p><strong>Hypoth\u00e8se principale.  <\/strong>Un DAI en plus des soins habituels augmentera la probabilit\u00e9 de survie chez les sujets dont la FEVG est comprise entre 36 % et 50 %, dont la DFM est alt\u00e9r\u00e9e et dont la MPT est anormale, mesur\u00e9e au moins 2 mois apr\u00e8s l&rsquo;infarctus du myocarde de r\u00e9f\u00e9rence.  <\/p>\n\n<p><strong>R\u00e9sultat.  <\/strong>La mortalit\u00e9 est le crit\u00e8re de jugement de la plupart des interventions cardiaques, car elle est impartiale et sans ambigu\u00eft\u00e9. En cas de r\u00e9sultat positif, la qualit\u00e9 de vie doit \u00eatre \u00e9valu\u00e9e pour faciliter l&rsquo;interpr\u00e9tation globale des r\u00e9sultats. En tant que tels, ces r\u00e9sultats constituent des r\u00e9sultats secondaires et ne seront \u00e9valu\u00e9s que si le r\u00e9sultat primaire est positif.  <\/p>\n\n<p><strong>Crit\u00e8res d&rsquo;inclusion :  <\/strong>18-80 ans, candidat au DAI cliniquement appropri\u00e9, FEVG de 36% \u00e0 50% mesur\u00e9e 2 mois apr\u00e8s l&rsquo;IM et au moins 3 mois apr\u00e8s une angioplastie ou un pontage, revascularisation si cliniquement indiqu\u00e9e, traitement m\u00e9dical appropri\u00e9, rythme sinusal dans les 8 semaines pr\u00e9c\u00e9dant l&rsquo;\u00e9valuation Holter, et HRT et TWA anormaux sur l&rsquo;\u00e9valuation Holter effectu\u00e9e 2 mois apr\u00e8s l&rsquo;IM (laboratoire central avec relecture par un expert). L&rsquo;essai est enregistr\u00e9 sur <a href=\"http:\/\/clinicaltrials.gov\/\" target=\"_blank\" rel=\"noreferrer noopener\">clinicaltrials.gov<\/a> (NCT00673842).<\/p>\n","protected":false},"featured_media":0,"menu_order":0,"template":"","class_list":["post-464","success","type-success","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Estimation du risque \u00e0 la suite d&#039;un infarctus \u00c9valuation non invasive - Efficacit\u00e9 du DAI (REFINE-ICD) - ACT AEC<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/act-aec.ca\/success\/risk-estimation-following-infarction-non-invasive-evaluation-icd-efficacy-refine-icd\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Estimation du risque \u00e0 la suite d&#039;un infarctus \u00c9valuation non invasive - Efficacit\u00e9 du DAI (REFINE-ICD) - ACT AEC\" \/>\n<meta property=\"og:description\" content=\"Synopsis de l&rsquo;essai REFINE ICD teste si un d\u00e9fibrillateur cardioverteur implantable (DCI), en plus des soins habituels, modifiera la mortalit\u00e9 par rapport aux soins habituels seuls. Au total, 700 patients pr\u00e9sentant une FEVG comprise entre 36 % et 50 %, une HRT alt\u00e9r\u00e9e et une TWA anormale, mesur\u00e9e au moins 2 mois apr\u00e8s l&rsquo;infarctus, sont [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/act-aec.ca\/success\/risk-estimation-following-infarction-non-invasive-evaluation-icd-efficacy-refine-icd\/\" \/>\n<meta property=\"og:site_name\" content=\"ACT AEC\" \/>\n<meta property=\"article:modified_time\" content=\"2023-11-10T22:20:58+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ACTAEC\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/act-aec.ca\/success\/risk-estimation-following-infarction-non-invasive-evaluation-icd-efficacy-refine-icd\/\",\"url\":\"https:\/\/act-aec.ca\/success\/risk-estimation-following-infarction-non-invasive-evaluation-icd-efficacy-refine-icd\/\",\"name\":\"Estimation du risque \u00e0 la suite d'un infarctus \u00c9valuation non invasive - Efficacit\u00e9 du DAI (REFINE-ICD) - ACT AEC\",\"isPartOf\":{\"@id\":\"https:\/\/act-aec.ca\/#website\"},\"datePublished\":\"2023-11-02T22:22:56+00:00\",\"dateModified\":\"2023-11-10T22:20:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/act-aec.ca\/success\/risk-estimation-following-infarction-non-invasive-evaluation-icd-efficacy-refine-icd\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/act-aec.ca\/success\/risk-estimation-following-infarction-non-invasive-evaluation-icd-efficacy-refine-icd\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/act-aec.ca\/success\/risk-estimation-following-infarction-non-invasive-evaluation-icd-efficacy-refine-icd\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/act-aec.ca\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Estimation du risque \u00e0 la suite d&#8217;un infarctus \u00c9valuation non invasive &#8211; Efficacit\u00e9 du DAI (REFINE-ICD)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/act-aec.ca\/#website\",\"url\":\"https:\/\/act-aec.ca\/\",\"name\":\"Accelerating Clinical Trials\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/act-aec.ca\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/act-aec.ca\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/act-aec.ca\/#organization\",\"name\":\"ACT Consortium\",\"url\":\"https:\/\/act-aec.ca\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/act-aec.ca\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/act-aec.ca\/wp-content\/uploads\/2023\/11\/63c97b160889232097514664_ACTAEC-Logo-1.svg\",\"contentUrl\":\"https:\/\/act-aec.ca\/wp-content\/uploads\/2023\/11\/63c97b160889232097514664_ACTAEC-Logo-1.svg\",\"width\":226,\"height\":76,\"caption\":\"ACT Consortium\"},\"image\":{\"@id\":\"https:\/\/act-aec.ca\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/ACTAEC\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Estimation du risque \u00e0 la suite d'un infarctus \u00c9valuation non invasive - Efficacit\u00e9 du DAI (REFINE-ICD) - ACT AEC","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/act-aec.ca\/success\/risk-estimation-following-infarction-non-invasive-evaluation-icd-efficacy-refine-icd\/","og_locale":"fr_FR","og_type":"article","og_title":"Estimation du risque \u00e0 la suite d'un infarctus \u00c9valuation non invasive - Efficacit\u00e9 du DAI (REFINE-ICD) - ACT AEC","og_description":"Synopsis de l&rsquo;essai REFINE ICD teste si un d\u00e9fibrillateur cardioverteur implantable (DCI), en plus des soins habituels, modifiera la mortalit\u00e9 par rapport aux soins habituels seuls. Au total, 700 patients pr\u00e9sentant une FEVG comprise entre 36 % et 50 %, une HRT alt\u00e9r\u00e9e et une TWA anormale, mesur\u00e9e au moins 2 mois apr\u00e8s l&rsquo;infarctus, sont [&hellip;]","og_url":"https:\/\/act-aec.ca\/success\/risk-estimation-following-infarction-non-invasive-evaluation-icd-efficacy-refine-icd\/","og_site_name":"ACT AEC","article_modified_time":"2023-11-10T22:20:58+00:00","twitter_card":"summary_large_image","twitter_site":"@ACTAEC","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/act-aec.ca\/success\/risk-estimation-following-infarction-non-invasive-evaluation-icd-efficacy-refine-icd\/","url":"https:\/\/act-aec.ca\/success\/risk-estimation-following-infarction-non-invasive-evaluation-icd-efficacy-refine-icd\/","name":"Estimation du risque \u00e0 la suite d'un infarctus \u00c9valuation non invasive - Efficacit\u00e9 du DAI (REFINE-ICD) - ACT AEC","isPartOf":{"@id":"https:\/\/act-aec.ca\/#website"},"datePublished":"2023-11-02T22:22:56+00:00","dateModified":"2023-11-10T22:20:58+00:00","breadcrumb":{"@id":"https:\/\/act-aec.ca\/success\/risk-estimation-following-infarction-non-invasive-evaluation-icd-efficacy-refine-icd\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/act-aec.ca\/success\/risk-estimation-following-infarction-non-invasive-evaluation-icd-efficacy-refine-icd\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/act-aec.ca\/success\/risk-estimation-following-infarction-non-invasive-evaluation-icd-efficacy-refine-icd\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/act-aec.ca\/"},{"@type":"ListItem","position":2,"name":"Estimation du risque \u00e0 la suite d&#8217;un infarctus \u00c9valuation non invasive &#8211; Efficacit\u00e9 du DAI (REFINE-ICD)"}]},{"@type":"WebSite","@id":"https:\/\/act-aec.ca\/#website","url":"https:\/\/act-aec.ca\/","name":"Accelerating Clinical Trials","description":"","publisher":{"@id":"https:\/\/act-aec.ca\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/act-aec.ca\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/act-aec.ca\/#organization","name":"ACT Consortium","url":"https:\/\/act-aec.ca\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/act-aec.ca\/#\/schema\/logo\/image\/","url":"https:\/\/act-aec.ca\/wp-content\/uploads\/2023\/11\/63c97b160889232097514664_ACTAEC-Logo-1.svg","contentUrl":"https:\/\/act-aec.ca\/wp-content\/uploads\/2023\/11\/63c97b160889232097514664_ACTAEC-Logo-1.svg","width":226,"height":76,"caption":"ACT Consortium"},"image":{"@id":"https:\/\/act-aec.ca\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/ACTAEC"]}]}},"_links":{"self":[{"href":"https:\/\/act-aec.ca\/fr\/wp-json\/wp\/v2\/success\/464","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/act-aec.ca\/fr\/wp-json\/wp\/v2\/success"}],"about":[{"href":"https:\/\/act-aec.ca\/fr\/wp-json\/wp\/v2\/types\/success"}],"wp:attachment":[{"href":"https:\/\/act-aec.ca\/fr\/wp-json\/wp\/v2\/media?parent=464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}